Andreas Evers

Dr. Andreas Evers

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AEAndreas Evers
Andreas Evers
THTorsten Haack
Torsten Haack
MLMartin Lorenz
Martin Lorenz
MBMartin Bossart
Martin Bossart
RERalf Elvert
Ralf Elvert
MWMichael Wagner
Michael Wagner

7 June 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AEAndreas Evers
Andreas Evers
MBMartin Bossart
Martin Bossart
SPStefania Pfeiffer-Marek
Stefania Pfeiffer-Marek
RERalf Elvert
Ralf Elvert
HSHerman Schreuder
Herman Schreuder
MWMichael Wagner
Michael Wagner

8 February 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AEAndreas Evers
Andreas Evers
DCDidier Clenet
Didier Clenet
SPStefania Pfeiffer-Marek
Stefania Pfeiffer-Marek
A crucial aspect of pharmaceutical development is the demonstration of long-term stability of the drug product. Biopharmaceuticals, such as proteins or peptides in liquid formulation, are typically administered via parental routes and should be stable over the shelf life, which generally includes a storing period (e.g., two years at 5 °C) and optionally an in-use period (e.g., 28 days at 30 °C). Herein, we present a case study where chemical degradation of SAR441255, a therapeutic peptide, in different formulations in combination with primary packaging materials was analyzed under accelerated conditions to derive long-term stability predictions for the recommended storing conditions (two years at 5 °C plus 28 days at 30 °C) using advanced kinetic modeling. These predictions served as a crucial decision parameter for the entry into clinical development. Comparison with analytical data measured under long-term conditions during the subsequent development phase demonstrated a high prediction accuracy. These predictions provided stability insights within weeks that would otherwise take years using measurements under long-term stability conditions only. To our knowledge, such in silico studies on stability predictions of a therapeutic peptide using accelerated chemical degradation data and advanced kinetic modeling with comparisons to subsequently measured real-life long-term stability data have not been described in literature before.

4 November 2024 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MEM. Frank Erasmus
M. Frank Erasmus
LSLaura Spector
Laura Spector
FFFortunato Ferrara
Fortunato Ferrara
RDRoberto DiNiro
Roberto DiNiro
TPThomas J. Pohl
Thomas J. Pohl
ABAndrew R. M. Bradbury
Andrew R. M. Bradbury

18 October 2024 in Protein Science
Verified
Journal Article
Open access
MFMonica Fernandez-Quintero
Monica Fernandez-Quintero
EGEnrico Guarnera
Enrico Guarnera
DMDjordje Musil
Djordje Musil
LPLukas Pekar
Lukas Pekar
CSCarolin Sellmann
Carolin Sellmann
AEAndreas Evers
Andreas Evers
The humanization of camelid‐derived variable domain heavy chain antibodies (VHHs) poses challenges including immunogenicity, stability, and potential reduction of affinity. Critical to this process are complementarity‐determining regions (CDRs), Vernier and Hallmark residues, shaping the three‐dimensional fold and influencing VHH structure and function. Additionally, the presence of non‐canonical disulfide bonds further contributes to conformational stability and antigen binding. In this study, we systematically humanized two camelid‐derived VHHs targeting the natural cytotoxicity receptor NKp30. Key structural positions in Vernier and Hallmark regions were exchanged with residues from the most similar human germline sequences. The resulting variants were characterized for binding affinities, yield, and purity. Structural binding modes were elucidated through crystal structure determination and AlphaFold2 predictions, providing insights into differences in binding affinity. Comparative structural and molecular dynamics characterizations of selected variants were performed to rationalize their functional properties and elucidate the role of specific sequence motifs in antigen binding. Furthermore, systematic analyses of next‐generation sequencing (NGS) and Protein Data Bank (PDB) data was conducted, shedding light on the functional significance of Hallmark motifs and non‐canonical disulfide bonds in VHHs in general. Overall, this study provides valuable insights into the structural determinants governing the functional properties of VHHs, offering a roadmap for their rational design, humanization, and optimization for therapeutic applications.

1 April 2019 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
AEAndreas Evers
Andreas Evers
SPStefania Pfeiffer-Marek
Stefania Pfeiffer-Marek
MBMartin Bossart
Martin Bossart
CHChristoph Heubel
Christoph Heubel
USUrsula Stock
Ursula Stock
MWMichael Wagner
Michael Wagner